Delving into the Latest Updates on Docosahexaenoic acid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid, 22:6-4, 7,10,13,16,19, 4,7,10,13,16,19-docosahexaenoic acid

+ [17]

Target-

Mechanism-

Therapeutic Areas

NeoplasmsNervous System DiseasesCardiovascular Diseases+ [5]

Active Indication

Chronic Kidney DiseasesVision DisordersNon-Small Cell Lung Cancer+ [5]

Inactive Indication

Anemia, Sickle CellAttention Deficit DisorderComplication+ [1]

Originator Organization

DSM Biomedical, Inc.

Active Organization

Texas A&M UniversityVeterans Administration Medical Center

University of Nevada

+ [4]

Inactive Organization

Micelle BioPharma, Inc.StartupDSM Nutritional Products LLC

Sancilio & Co., Inc.

Drug Highest PhasePreclinical

First Approval Date-

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC22H32O2

InChIKeyMBMBGCFOFBJSGT-KUBAVDMBSA-N

CAS Registry6217-54-5

The functional and structural integrity of the blood–brain barrier is crucial in maintaining homeostasis in the brain microenvironment; however, the molecular mechanisms underlying the formation and function of the blood–brain barrier remain poorly understood. The major facilitator superfamily domain containing 2A has been identified as a key regulator of blood–brain barrier function. It plays a critical role in promoting and maintaining the formation and functional stability of the blood–brain barrier, in addition to the transport of lipids, such as docosahexaenoic acid, across the blood–brain barrier. Furthermore, an increasing number of studies have suggested that major facilitator superfamily domain containing 2A is involved in the molecular mechanisms of blood–brain barrier dysfunction in a variety of neurological diseases; however, little is known regarding the mechanisms by which major facilitator superfamily domain containing 2A affects the blood–brain barrier. This paper provides a comprehensive and systematic review of the close relationship between major facilitator superfamily domain containing 2A proteins and the blood–brain barrier, including their basic structures and functions, cross-linking between major facilitator superfamily domain containing 2A and the blood–brain barrier, and the in-depth studies on lipid transport and the regulation of blood–brain barrier permeability. This comprehensive systematic review contributes to an in-depth understanding of the important role of major facilitator superfamily domain containing 2A proteins in maintaining the structure and function of the blood–brain barrier and the research progress to date. This will not only help to elucidate the pathogenesis of neurological diseases, improve the accuracy of laboratory diagnosis, and optimize clinical treatment strategies, but it may also play an important role in prognostic monitoring. In addition, the effects of major facilitator superfamily domain containing 2A on blood–brain barrier leakage in various diseases and the research progress on cross-blood–brain barrier drug delivery are summarized. This review may contribute to the development of new approaches for the treatment of neurological diseases.

01 Feb 2025·Food Chemistry

Preparation of dehydroabietic acid modified chitosan/wintergreen essential oil film and mandarin freshness preservation study

Article

Author: Shi, Zhengjun ; Li, Lingling ; Chen, Qian ; Xu, Kaimeng ; Niu, Yanfei ; Wu, Chunhua ; Rao, Xiaoping

In order to obtain an eco-friendly and multifunctional preservative film, dehydroabietic acid (DHA) modified chitosan (CS) containing wintergreen essential oil (CSDA-WEO) film was developed. CS grafted by DHA was able to increase the deformation capacity of CS film (MCS) by about 12.5 %, and the film made by CSDA containing WEO increased the tensile deformation capacity to 32 %. CSDA-WEO film (MCSDA-WEO) can improve the transmittance and UV blocking, and MCSDA-WEO can be completely degraded within 35 days. In the Film-2 approach, PE film (MPE), CSDA film (MCSDA) and MCSDA-WEO again improve the preservative performance based on the original 1 approach and have good freshness preservation. MCSDA and MCSDA-WEO were able to delay the loss of antioxidant activity, improve the antifungal property and prolong the shelf life of mandarins up to 18 days. MCSDA and MCSDA-WEO have good performance, are green and healthy, and have a wide perspective for food preservation.

01 Feb 2025·Current Pediatric Reviews

The Effectiveness of Perinatal Omega-3 Supplements in Neurodevelopment and Physical Growth of 9- and 12-month-old Infants: A Follow-up of a Clinical Trial

Article

Author: Sarrafi, Somayyeh ; Farshbaf-Khalili, Azizeh ; Shakouri, Seyed Kazem ; Pourzeinali, Samira ; Ostadrahimi, Alireza

Background:Omega-3 fatty acids (FAs) are essential long-chain polyunsaturated fatty acids (LCPUFAs) that are essential for optimal health and development.Objective:The present study aimed to evaluate the effectiveness of maternal fish oil (containing omega-3 LCPUFA) intake from 21th week of pregnancy to 30 days postpartum for neurodevelopment and growth of infants at 9 and 12 months.Methods:This was a follow-up study of a triple-blinded clinical trial. The study population was 9-- month-old infants. Their mothers were randomly divided into two groups of 75 people with a 1:1 ratio to take one fish oil supplement or a placebo daily. The anthropometric indicators of infants at months 9 and 12 and neurodevelopment at month 12 by the ASQ questionnaire were measured. In the fish oil and placebo groups, respectively, 73 and 71 infants at nine months, as well as 71 and 69 at 12 months, were analyzed.Results:No statistically significant impact was observed following consuming omega-3 capsules on the neurodevelopmental domains, growth parameters, and the profile of maternal serum FAs (p > 0.05) except DHA. Neurodevelopmental problems were illustrated in one case in the intervention group and two cases in the placebo group.Conclusion:Perinatal relatively low-dose omega-3 LCPUFAs supplements indicated no statistically significant impacts on the growth and neurodevelopment of 9- and 12-month-old infants in a population with low consumption of marine products. Further studies investigating the effect of higher doses of omega-3 LCPUFAs are suggested.

76

News (Medical) associated with Docosahexaenoic acid

16 Aug 2024

·www.businesswire.com

Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.

VANCOUVER, British Columbia--( BUSINESS WIRE )-- Lobe Sciences, Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) , a biopharmaceutical company focused on developing products to treat diseases with unmet medical needs, today announced that is has formed a wholly owned U.S. subsidiary named Alera Pharma, Inc. (Alera). Alera will be assigned the intellectual property rights focused on the Company’s neurological assets and its new chemical entity Psilocin Mucate. Mr. Rick Goulburn has been appointed as the Chief Executive Officer of Alera. Dr. Fred D. Sancilio will be Chairman of its Board of Directors and be joined on the board by Dr. Harry Jacobson, Mr. Wesley Ramjeet and Mr. Goulburn. Alera will be the operating company within the Lobe Sciences group focused on neurology and will join Altemia, LLC as the second operating subsidiary of Lobe Sciences. It is expected that the Company’s Australian subsidiary, Lobe Sciences Australia Pty Ltd., will become a subsidiary of Alera. Mr. Ilan Hayman will become a member of the executive management team of Alera. Dr. Sancilio, Chairman and CEO of Lobe Sciences said, “At present, Lobe Sciences has a complex corporate structure. By establishing Alera Pharma, we are simplifying the operations of the Company into just three entities. Lobe Sciences, Ltd will provide common services to the two operating subsidiaries - Alera and Altemia, LLC. The creation of two separate operating companies will allow each entity to create value within their respective therapeutic areas; neurology and hematology.” The Company also announces the receipt from the US PTO of a Notice of Allowance for its U.S. Patent Application Serial No. 18/411,576. About Lobe Sciences Ltd. Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaboration with industry-leading partners, is engaged in novel research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolio, and intends to initiate the launch of Altemia ® , a medical food designed to meet the needs of sickle cell patients globally. Cautionary Statement Regarding "Forward-Looking" Information This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the composition of the management team of Alera and the ownership of Lobe Sciences Australia Pty Ltd., are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the management team of Alera will be appointed as currently expected and that Lobe Sciences Australia Pty Ltd. will become a subsidiary of Alera as currently anticipated. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the management team of Alera will be appointed differently as currently expected and that Lobe Sciences Australia Pty Ltd. will not become a subsidiary of Alera as currently anticipated. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

Executive ChangePhase 1Phase 2

19 Jul 2024

·www.drugs.com

Micronutrient Supplementation Slows Geographic Atrophy Progression

FRIDAY, July 19, 2024 -- Oral micronutrient supplementation slows geographic atrophy (GA) progression in age-related macular degeneration (AMD), according to a study published online July 16 in Ophthalmology . Tiarnan D.L. Keenan, B.M., B.Ch., Ph.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues examined whether oral supplements slow GA progression in AMD in a post-hoc analysis of the Age-Related Eye Diseases Study (AREDS) and AREDS2 multicenter, randomized trials. A total of 392 eyes from 318 participants with GA were included in AREDS, and 1,210 eyes from 891 participants with GA were included in AREDS2. AREDS participants were randomly allocated to oral antioxidants; zinc (80 mg); combination; or placebo. AREDS2 participants were randomly assigned to lutein/zeaxanthin; docosahexaenoic acid/eicosapentaenoic acid; combination; or placebo. AREDS2 participants were also randomly assigned to alternative AREDS formulations: original, no β-carotene, zinc (25 mg), or both. The researchers found that proximity-based progression toward the central macula was significantly slower in AREDS eyes with noncentral GA with randomization to antioxidants versus none (50.7 versus 72.9 µm/year). In AREDS2 eyes with noncentral GA, proximity-based progression was significantly slower with randomization to lutein/zeaxanthin versus none among those assigned to AREDS antioxidants without β-carotene (80.1 versus 114.4 µm/year). Area-based progression was not significantly different with randomization to antioxidants versus none in AREDS2 eyes with any GA. "We've known for a long time that AREDS2 supplements help slow the progression from intermediate to late AMD. Our analysis shows that taking AREDS2 supplements can also slow disease progression in people with late dry AMD," Keenan said in a statement. "These findings support the continued use of AREDS2 supplements by people with late dry AMD." Several authors disclosed ties to the pharmaceutical industry.

Clinical Result

10 Jul 2024

·www.drugs.com

Adherence to Mediterranean Diet, Omega-3 Fatty Acids Beneficial in Acne

WEDNESDAY, July 10, 2024 -- Adherence to a Mediterranean diet incorporating eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) reduces skin lesions and improves quality of life in patients with acne, according to a study published online July 10 in the Journal of Cosmetic Dermatology . Anne Guertler, M.D., from Ludwig Maximilian University in Munich, and colleagues examined the clinical effects associated with increasing EPA/DHA levels in patients with acne. Sixty participants without prescription medication (23 with acne comedonica [AC] and 37 with acne papulopustulosa [AP]) adhered to a Mediterranean diet, incorporating omega-3 fatty acid supplementation. Blood EPA/DHA levels were tracked at four visits (V1 to V4) using the HS-omega 3 index (EPA/DHA [percent] of total identified fatty acids in erythrocytes: target, 8 to 11 percent; deficit, <8 percent; severe deficit, <4 percent). The researchers found that 98.3 percent of patients had an EPA/DHA deficit at baseline, with the mean HS-omega 3 index increasing from 4.9 to 8.3 percent at V1 to V4. At V4, significantly higher indices were seen for AC than AP. In both inflammatory and noninflammatory lesions, there were objective improvements observed. Four patients self-reported worsened appearance, but overall quality of life improved, especially in AP. Compared with beneficial foods, dietary triggers were more clearly defined. Cow's milk and dairy product intake was reduced. A high rate of compliance was observed, and there were no reports of adverse events. "Lifestyle interventions, including dietary recommendations, should not be considered in opposition to prescription medications, but rather as a valuable adjunct to any modern acne treatment plan," Guertler said in a statement. Omegametrix® GmbH performed the analysis of the HS-omega-3 Index® free of charge. Queisser Pharma GmbH & Co. KG offered omega-3 supplements free of charge.

Clinical Result

100 Deals associated with Docosahexaenoic acid

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Docosahexaenoic acid	V06D	DB03756

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anemia, Sickle Cell	Phase 2	-	Micelle BioPharma, Inc.Startup	01 Mar 2019
Complication	Phase 2	-	Micelle BioPharma, Inc.Startup	01 Mar 2019
Attention Deficit Disorder	Phase 2	US	DSM Nutritional Products LLC	01 Sep 2013
Coronary Disease	Preclinical	US	Veterans Administration Medical Center	30 Oct 2012
Colorectal Cancer	Preclinical	US	Texas A&M University	15 Apr 2010
Breast Cancer	Preclinical	US	University of Nevada	01 May 2009
Adenocarcinoma of Lung	Preclinical	US	University of Nevada	01 May 2008
Colonic Cancer	Preclinical	US	University of Nevada	01 May 2008
Hypertriglyceridemia	Discovery	-	Sancilio & Co., Inc.	28 Nov 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2024	Not Applicable	Cardiovascular Diseases	-	Eicosapentaenoic acid (EPA)	(zgevvigedh) = myjensdeqq ixgyqjxynv (qkplmghicw, 0.95 - 0.98)	-	02 Sep 2024
				Docosahexaenoic acid (DHA)	(zgevvigedh) = bxgnyybgcz ixgyqjxynv (qkplmghicw, 0.86 - 0.89)
NCT03965988 (Pubmed \| Pediatr Neurol)	Phase 3	Syncope	-	Docosahexaenoic Acid (DHA) plus Piracetam	drbaicitnp(hfdihneidz) = srasnjxact adhcoxxyww (xkopjxcswz )	Positive	01 Nov 2023
				Piracetam plus Placebo	drbaicitnp(hfdihneidz) = kqiskdcygb adhcoxxyww (xkopjxcswz )
ARVO2023	Not Applicable	Glaucoma	-	DHA and Citicoline	okmjkifnix(ohgboltdst) = likwydkggf pjnealdein (zfwgbhxxyo ) View more	Positive	23 Apr 2023
NCT01883817 (CTgov)	Phase 3	Attention Deficit Disorder	30	Placebo (Placebo)	meawzhczva(jyyrmxvmta) = btzaicnffn egqzydhixf (okzkqxgpwb, itlzqkhywj - sfsynxkyuw) View more	-	16 Mar 2022
				DHA Omega-3 (DHA Omega-3)	meawzhczva(jyyrmxvmta) = vxnypkcdbp egqzydhixf (okzkqxgpwb, bthocghxop - gejrwwuqzv) View more
NCT01849250 (CTgov)	Phase 2	Triple Negative Breast Cancer \| Fibrocystic Breast Disease \| Invasive Mammary Carcinoma \| Breast Cancer 3 \| Mammary Paget's Disease \| Precancerous Conditions	65	Placebo (Placebo)	czjlatnfue(tzfyxkroue) = kckwreesrt bmjxpfmcog (rthvxiijuw, bublmcdepf - ioigyjhcfq) View more	-	28 Dec 2021
				Docosahexaenoic Acid (Docosahexaenoic Acid)	czjlatnfue(tzfyxkroue) = cjbrvhhsgk bmjxpfmcog (rthvxiijuw, ktrznrizmi - mygvvjwvgh) View more
NCT03784963 (CTgov)	Phase 1/2	Gastrointestinal Hemorrhage \| Heart Failure	35	Omega 3 fatty acids (Primary Prevention Intervention)	oodolugyen(ezljugtpvk) = puhalbmszt oahkeqjdms (iaktmlzvvg, dxnjrguclr - okqsmhjapl) View more	-	13 Jul 2021
				Placebo (Primary Prevention Non-Intervention)	oodolugyen(ezljugtpvk) = idvprueriu oahkeqjdms (iaktmlzvvg, tddxciigod - pwwpmhzhtn) View more
NCT02626299 (Pubmed)	Phase 3	Pregnancy \| Obstetric Labor, Premature	1,100	1000 mg DHA	fhkskymheb(nekchbvaff) = lvvxpsvjgd wzahjdebgx (jlzauvjivj )	Positive	01 Jun 2021
				200 mg DHA	fhkskymheb(nekchbvaff) = zxqpcnwqey wzahjdebgx (jlzauvjivj )
NCT01903525 (CTgov)	Phase 1	Athletic Injuries \| Brain Concussion	40	Placebo (Placebo)	gffhvkorrf(qmnkrrtxbl) = ebidmwvxon yrpxlilkeq (scbzvtmear, rosvfpdxrz - eacrkpyxsk) View more	-	11 Jan 2021
				Docosahexaenoic acid (DHA) (Docosahexaenoic Acid (DHA))	gffhvkorrf(qmnkrrtxbl) = jnneejzinf yrpxlilkeq (scbzvtmear, gzflsakzfp - ebmurtlqkf) View more
Pubmed \| Adv Nutr	Not Applicable	-	-	Docosahexaenoic Acid (DHA)	(blbskdmjne) = uzrxkmeilx sjmcuxkrhy (hyplgkkfbl, -0.57 to 0.85) View more	-	01 Jan 2021
NCT00467818 (CTgov)	Not Applicable	Autism Spectrum Disorder \| Autistic Disorder	17	Omega 3 fatty acids (Omega 3 Fatty Acids, Drug)	xhzqsplxtm(wbgumhixfu) = gmghkmgtkb qmxkqlppvb (mzguywlhjn, tyicqjrdqn - blndcixcjj) View more	-	16 Dec 2020
				Placebo (Placebo)	xhzqsplxtm(wbgumhixfu) = sjjagktjfd qmxkqlppvb (mzguywlhjn, hlcwbdttro - ryvucbzonp) View more